-+ 0.00%
-+ 0.00%
-+ 0.00%

LYELL IMMUNOPHARMA PROVIDES UPDATE ON SAFETY PROFILE OF LYL273 IN RELAPSED OR REFRACTORY METASTATIC COLORECTAL CANCER AND AMENDS PHASE 1 TRIAL TO PHASE 1/2 EXPANSION

Reuters·06/08/2026 10:00:00

Please log in to view news